PF 07225570
Alternative Names: PF-07225570Latest Information Update: 11 Nov 2022
At a glance
- Originator Pfizer
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Bladder cancer
Most Recent Events
- 04 Nov 2022 Pfizer withdraws phase I trial in Bladder cancer in the US and Poland (NCT05259397)
- 24 Mar 2022 Phase-I clinical trials in Bladder cancer (Monotherapy, Recurrent) in USA (Intravesicular) (NCT05259397)
- 04 Mar 2022 Preclinical trials in Bladder cancer in USA (IV) (Before March 2022)